Glomerular Disease Study and Trial Consortium (EIN 862088226) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2021

Legal Domicile

Principal Officer

Dr Ali Poyan Mehr

Phone

2039277987

Tax Period

2023-01-01 to 2023-12-31

Glomerular Disease Study and Trial Consortium, founded in 2021, is a small nonprofit in the Medical Research sector that reported $935K in total revenue in fiscal year 2023. Revenue surged 192% from the prior year, signaling strong growth momentum. The organization ran a surplus of $704K, a strong 75% operating margin.

Mission

The primary purposes of the corporation shall be to raise awareness about, promote diagnosis and treatment of, and help patients with kidney diseases.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $629,958

Program Service Revenue $305,479

Investment Income $0

Other Revenue $0

TOTAL REVENUE $935,437

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $205,328

Other Expenses $230,972

TOTAL EXPENSES $230,972

Year-over-Year Comparison

	2023	2022	Change
Revenue	$935,437	$320,412	+1.9%
Expenses	$230,972	$92,317	+1.5%
Net Income	$704,465	$228,095	+2.1%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Dr Maria Ansari	Board Member	0.25	Director	$0	$0	$0
Dr Martin Pollak	Board Member	0.25	Director	$0	$0	$0
Dr Ali Poyan Mehr	President	10.00	Officer	$0	$0	$0
Dr Tingting Li	Secretary	0.25	Officer	$0	$0	$0
Olga Yurchenko	CFO/Treasurer	0.50	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$935,437	$230,972	$968,603	$704,465
2022	$320,412	$92,317	$264,096	$228,095

Glomerular Disease Study and Trial Consortium